Current Status of Rift Valley Fever Vaccine Development.
about
Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination.A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting.Rift valley fever viral load correlates with the human inflammatory response and coagulation pathway abnormalities in humans with hemorrhagic manifestations.
P2860
Current Status of Rift Valley Fever Vaccine Development.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Current Status of Rift Valley Fever Vaccine Development.
@en
type
label
Current Status of Rift Valley Fever Vaccine Development.
@en
prefLabel
Current Status of Rift Valley Fever Vaccine Development.
@en
P2093
P2860
P356
P1433
P1476
Current Status of Rift Valley Fever Vaccine Development.
@en
P2093
Angelle Desiree LaBeaud
Bonto Faburay
D Scott McVey
Juergen A Richt
P2860
P356
10.3390/VACCINES5030029
P577
2017-09-19T00:00:00Z